Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MDM4 | O15151 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.37 |
| ▸ | CASP3 | P42574 | 2/20 | 0.37 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.36 |
| ▸ | FABP7 | O15540 | 2/20 | 0.36 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.36 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.36 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28737117 | 1.00 | KMT2A (0.37) | KMT2AMDM4TP53CASP3FABP5 | |
| SCHEMBL8892691 | 0.90 | KMT2A (0.38) | KMT2AMDM4TP53CASP3FABP5 | |
| SCHEMBL2133987 | 0.85 | MDM2 (0.38) | KMT2AMDM4TP53CASP3FABP5 | |
| SCHEMBL22610140 | 0.85 | MDM2 (0.38) | KMT2AMDM4TP53CASP3FABP5 | |
| SCHEMBL31369691 | 0.85 | MDM4 (0.38) | KMT2AMDM4TP53CASP3FABP5 | |
| SCHEMBL23042936 | 0.85 | MDM4 (0.37) | KMT2AMDM4TP53CASP3FABP5 | |
| SCHEMBL29879964 | 0.85 | MDM4 (0.37) | KMT2AMDM4TP53CASP3FABP5 | |
| SCHEMBL7517501 | 0.85 | MDM4 (0.37) | KMT2AMDM4TP53CASP3FABP5 | |
| SCHEMBL29633641 | 0.85 | PTPRA (0.42) | KMT2AMDM4TP53CASP3FABP5 | |
| SCHEMBL26071690 | 0.83 | MDM4 (0.38) | KMT2AMDM4TP53CASP3FABP5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171494-A1 | METHOD FOR SYNTHESIZING PEPTIDE CONTAINING N-SUBSTITUTED AMINO ACID | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-05-29 | — | — | US | disclosed |
| US-12281141-B2 | Method for synthesizing peptide containing N-substituted amino acid | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-04-22 | — | — | US | disclosed |
| CN-118772227-A | Method for synthesizing peptides containing N-substituted amino acids | 中外制药株式会社 | 2024-10-15 | — | — | CN | disclosed |
| CN-110799520-B | Method for synthesizing peptides containing N-substituted amino acids | 中外制药株式会社 | 2024-07-12 | — | — | CN | disclosed |
| CN-118256591-A | Cyclic peptide compound having high membrane permeability and library comprising same | 中外制药株式会社 | 2024-06-28 | — | — | CN | disclosed |
| CN-110869544-B | Cyclic peptide compound having high membrane permeability and library comprising same | 中外制药株式会社 | 2024-03-08 | — | — | CN | disclosed |
| US-20230406879-A1 | METHOD FOR SYNTHESIZING PEPTIDE CONTAINING N-SUBSTITUTED AMINO ACID | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-12-21 | — | — | US | disclosed |
| US-11787836-B2 | Method for synthesizing peptide containing N-substituted amino acid | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-10-17 | — | — | US | disclosed |
| US-20230138226-A1 | METHOD FOR SYNTHESIZING PEPTIDE CONTAINING N-SUBSTITUTED AMINO ACID | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-04 | — | — | US | disclosed |
| US-11542299-B2 | Method for synthesizing peptide containing N-substituted amino acid | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-01-03 | — | — | US | disclosed |
| EP-2983722-A1 | MODULATION OF STRUCTURED POLYPEPTIDE SPECIFICITY | Bicycle Therapeutics Limited (GB) | 2016-02-17 | — | — | EP | disclosed |
| WO-2014167122-A1 | MODULATION OF STRUCTURED POLYPEPTIDE SPECIFICITY | BICYCLE THERAPEUTICS LIMITED (GB) | 2014-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250171494-A1 | METHOD FOR SYNTHESIZING PEPTIDE CONTAINING N-SUBSTITUTED AMINO ACID | NPPA, VIP, DNPEP | KMT2A 2263/4885MDM4 4142/4885TP53 2781/4885 |
| US-12281141-B2 | Method for synthesizing peptide containing N-substituted amino acid | NPPA, VIP, DNPEP | KMT2A 2263/4885MDM4 4142/4885TP53 2781/4885 |
| US-20230406879-A1 | METHOD FOR SYNTHESIZING PEPTIDE CONTAINING N-SUBSTITUTED AMINO ACID | NPPA, VIP, DNPEP | KMT2A 2263/4885MDM4 4142/4885TP53 2781/4885 |
| US-20230138226-A1 | METHOD FOR SYNTHESIZING PEPTIDE CONTAINING N-SUBSTITUTED AMINO ACID | NPPA, VIP, DNPEP | KMT2A 2263/4885MDM4 4142/4885TP53 2781/4885 |
| US-11542299-B2 | Method for synthesizing peptide containing N-substituted amino acid | NPPA, VIP, DNPEP | KMT2A 2263/4885MDM4 4142/4885TP53 2781/4885 |
| US-11787836-B2 | Method for synthesizing peptide containing N-substituted amino acid | NPPA, VIP, DNPEP | KMT2A 2263/4885MDM4 4142/4885TP53 2781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.